DoD Awards Genomind Contract to Implement Pharmacogenomics Testing for Active-Duty Service Members
Key Insights
Genomind (search) has been awarded a Department of Defense (search) contract to pilot pharmacogenomics testing for active-duty service members through the Defense Health Agency (search)'s Research & Engineering Directorate.
The program aims to integrate genetic insights into the Military Health System (search)'s GENESIS electronic health records to optimize medication management and reduce adverse drug reactions (search).
The initiative seeks to improve healthcare delivery outcomes for service members while enhancing operational readiness and reducing total cost of care through personalized prescribing decisions.
Genomind (search), a precision medicine and pharmacogenomic testing company, has secured a contract from the Department of Defense (search) to implement and assess pharmacogenomics for U.S. active-duty service members. The project, titled "Implementing and Assessing Pharmacogenomics for U.S. Active-Duty Service members," receives funding through the FY24 Department of Defense Appropriations Act.
Partnership with Defense Health Agency
The initiative represents a collaboration between Genomind (search), the Defense Health Agency (search)'s Research & Engineering Directorate, and the Clinical Genomics and Precision Medicine Office (search). The Clinical Genomics and Precision Medicine Office will play a crucial role in capturing, analyzing, and implementing patients' genetic information into the Military Health System (search)'s GENESIS electronic health record.
Program Objectives and Implementation
The program's primary purpose is to identify how pharmacogenomics may aid in treating specific medical conditions to improve healthcare delivery and outcomes for active-duty service members. The initiative will specifically evaluate how genetic insights can be embedded into medical records to optimize medication management, with the goal of reducing adverse drug reactions (search) and other health complications.
Under the contract terms, Genomind (search) will provide consulting services and leverage its decades of pharmacogenomics expertise to guide the assessment and implementation of pharmacogenomics within the Department of Defense (search) Military Health System (search).
Clinical Impact and Strategic Goals
"Pharmacogenomics has the power to transform how we approach prescribing decisions for both mental and physical health," said Daniel Dowd, Chief Clinical Officer at Genomind (search). "We are honored to partner with the Defense Health Agency (search) on this important initiative that has the potential to improve the health, safety, and operational readiness of America's military, all while reducing the total cost of care."
The project aligns with Genomind (search)'s mission to transform lives and renew hope for patients by delivering actionable genetic insights that help providers personalize care, reduce trial-and-error prescribing, and enhance patient outcomes.
Funding and Administrative Details
The effort is sponsored by the Department of Defense (search) under Other Transaction Number W81XWH-15-9-0001 through the Medical Technology Enterprise Consortium (search). The contract represents a significant step toward integrating precision medicine approaches into military healthcare systems, potentially setting a precedent for broader implementation across defense medical facilities.